<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166483">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01888198</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC 13-116</org_study_id>
    <nct_id>NCT01888198</nct_id>
  </id_info>
  <brief_title>Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment</brief_title>
  <official_title>Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KAISER SAN RAPHAEL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee Medical Center, Knoxville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, Baltimore County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Diego Imaging Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand how effective ablation is for destroying
      tumor cells in the kidney and whether quality of life is improved for patients.
      Participation in ARMOR may involve retrospective data collection only, combined
      retrospective and prospective data collection, or prospective data collection
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>assess renal ablation outcomes</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess renal ablation outcomes using standard quality of life measures. Specifically, quality of life outcomes measures will be analyzed with respect to ablation procedure characteristics including ablation technique and anesthesia type as well as renal mass characteristics such as size, location and pathologic tumor type.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>differences in imaging characteristics</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>between CT and MR related to renal ablation. We hypothesize that, after ablation, the observed relative change in contrast enhancement at the site of ablation for each follow-up time point will be similar for tumors imaged by CT compared with those imaged by MR. This objective will be met by observational and descriptive methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the progression of imaging findings</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>in terms of size and contrast enhancement at the site of renal ablation, correlated with ablation technology and tumor histopathology. The objective is to determine whether the choice of imaging method, ablation technique, or histopathologic tumor subtype will be associated with similar relative change in contrast enhancement and size after ablation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation exposure</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>associated with CT imaging performed during an ablation procedure and subsequent imaging follow-up to 2 years. Radiation dose will be analyzed using multivariable linear regression, with ablation technique as the primary predictor.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>renal mass ablation candidates</arm_group_label>
    <description>Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>(EORTC QLQ-C30) questionnaire</intervention_name>
    <arm_group_label>renal mass ablation candidates</arm_group_label>
    <other_name>European Organization for Research and Treatment of Cancer 30-item</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EuroQol EQ-5D 7-item questionnaire</intervention_name>
    <arm_group_label>renal mass ablation candidates</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients at MSKCC will be identified and recruited from the existing patient
        population in the Interventional Radiology Service in the Department of Radiology. At all
        other participating sites, patients meeting eligibility criteria will be identified by the
        site investigators that have received the referral for consideration of renal mass
        ablation. Participation in ARMOR may involve retrospective data collection only, combined
        retrospective and prospective data collection, or prospective data collection
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Retrospective enrollment:

        - Patients having undergone percutaneous, open or laparoscopic energy ablation of a renal
        mass.

        Prospective enrollment:

        - Patients scheduled to undergo, rather than having undergone, percutaneous, open or
        laparoscopic energy ablation of a renal mass.

        Exclusion Criteria:

          -  Patients not having undergone, or considered candidates for percutaneous, open or
             laparoscopic energy ablation of a renal mass

          -  Non-English speaking patients

          -  Patients under the age of 18.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Durack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy Durack, MD</last_name>
    <phone>212-639-4898</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Solomon, MD</last_name>
    <phone>212-639-5012</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Howard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard Howard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Durack, MD</last_name>
      <phone>212-639-4898</phone>
    </contact>
    <contact_backup>
      <last_name>Stephen Solomon, MD</last_name>
      <phone>212-639-5012</phone>
    </contact_backup>
    <investigator>
      <last_name>Jeremy Durack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia,</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colette Shaw, MD</last_name>
    </contact>
    <investigator>
      <last_name>Colette Shaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian Dupuy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Damian Dupuy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ablation</keyword>
  <keyword>quality of Life (QOL)</keyword>
  <keyword>kidney</keyword>
  <keyword>registry</keyword>
  <keyword>Ablation of Renal Masses Outcomes Registry (ARMOR)</keyword>
  <keyword>13-116</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
